Trials / Unknown
UnknownNCT01572688
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melphalan | powder for injection, 200mg/m2, uses after reconstituted within 24 hours |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2012-04-06
- Last updated
- 2012-08-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01572688. Inclusion in this directory is not an endorsement.